

Unlocking the predictive potential of cancer organoids with AI-powered computer vision and data processing


Abraham Lin^{1,2}, Maxim Le Compte^{1,2}, Edgar Cardenas De La Hoz¹, Tyler Gilcrest¹, Christophe Deben^{1,2}

¹Orbits Oncology, San Francisco, USA

²Center for Oncological Research, University of Antwerp, Belgium



EARLY RESEARCH




Cells

Animals



“It’s time to bring patient insights into early cancer drug discovery”

CLINICAL TRIALS




Patients

ADVANCED BIOLOGY

Patient-derived organoids are the most human-like cancer models

Organoids retain:


- Patient genetics
- Patient mutations
- Patient tumor architecture
- Patient diversity



Promising for novel drug research, but very difficult to analyze

ADVANCED IMAGE ANALYSIS

AI-powered digital platform to extract therapeutically relevant metrics from organoid imagery



CLINICAL INSIGHTS

Combining biology with AI enables precision cancer drug discovery



Understand Drug Mechanism



Predict Patient Response




Identify Biomarkers



Automate Processes

ORBITS ONCOLOGY ANALYSIS OUTPERFORMS INDUSTRY STANDARD




BETTER RESOLUTION

- Monitor lifecycle of organoids over time
- Analyze organoids at the single-organoid population level
- Quantify intratumoral heterogeneity and response to drugs
- Understand how novel drugs work


HIGHER CORRELATION TO PATIENT

- Predict patient response to novel drugs
- Identify potential for therapy resistance
- Select the best drugs to move into clinical trial
- Match the right drugs to the right patients



MORE INFORMATION

- Follow on LinkedIn
- Read our publications
- Watch our demo
- Visit our website



Contact us:
Dr. Abraham Lin
CEO, Orbits Oncology
abraham.lin@orbits-oncology.com



Orbits Oncology
3175 Hanover St
Palo Alto, CA, USA 94304

<https://www.orbits-oncology.com/>

Industry Engagements:

